Copy number variants (CNVs) are the gain or loss of DNA segments in the genome that can vary in dosage and length. CNVs comprise a large proportion of variation in human genomes and impact health conditions. To detect rare CNV association, kernel-based methods have been shown to be a powerful tool because their flexibility in modeling the June 2, 2019 1/27 aggregate CNV effects, their ability to capture effects from different CNV features, and their ability to accommodate effect heterogeneity. To perform a kernel association test, a CNV locus needs to be defined so that locus-specific effects can be retained during aggregation. However, CNV loci are arbitrarily defined and different locus definitions can lead to different performance depending on the underlying effect patterns. In this work, we develop a new kernel-based test called CONCUR (i.e., Copy Number profile Curve-based association test) that is free from a definition of locus and evaluates CNV-phenotype association by comparing individuals' copy number profiles across the genomic regions. CONCUR is built on the proposed concepts of "copy number profile curves" to describe the CNV profile of an individual, and the "common area under the curve (cAUC) kernel" to model the multi-feature CNV effects. Compared to existing methods, CONCUR captures the effects of CNV dosage and length, accounts for the continuous nature of copy number values, and accommodates between-and within-locus etiological heterogeneities without the need to define artificial CNV loci as required in current kernel methods. In a variety of simulation settings, CONCUR shows comparable and improved power over existing approaches. Real data analyses suggest that CONCUR is well powered to detect CNV effects in gene pathways associated with phenotypes using data from the Swedish Schizophrenia Study and the Taiwan Biobank. Author summary Copy number variants comprise a large proportion of variation in human genomes. Large rare CNVs, especially those disrupting genes or changing the dosages of genes, can carry relatively strong risks for neurodevelopmental and neuropsychiatric disorders. Kernel-based association methods have been developed for the analysis of rare CNVs and shown to be a valuable tool. Kernel methods model the collective effect of rare CNVs using flexible kernel functions that capture the characteristics of CNVs and measure CNV similarity of individual pairs. Typically kernels are created by summarizing similarity within an artificially defined "CNV locus" and then collapsing across all loci. In this work, we propose a new kernel-based test, CONCUR, that is based on the CNV location information contained in standard processing of the variants and removes the need for any arbitrarily defined CNV loci. CONCUR quantifies June 2, 2019 2/27 similarity between individual pairs as the common area under their copy number profile curves and is designed to detect CNV dosage, length and dosage-length interaction effects. In simulation studies and real data analysis, we demonstrate the ability of CONCUR test to detect CNV effects under diverse CNV architectures with power and robustness over existing methods.
evaluated at the same single base-pair position (referred to as a locus) across 48 individuals, it is natural to assess similarity locus-by-locus and aggregate the locus-level 49 similarity over all loci in the target region to obtain an overall SNP similarity. A locus 50 unit for CNVs, however, is not so obvious since CNVs span multiple base pairs and may 51 overlap partially between individuals. 52 To address this issue, standard CNV kernel-based tests construct CNV regions 53 (CNVR). For example, the CNV Collapsing Random Effects Test (CCRET) [6] creates 54 CNVR by clustering CNV segments of different individuals with some arbitrary amount 55 of overlap (e.g., 1 base pair overlap, 50% reciprocal overlap). With CNVRs, the CNV al. [6] . Briefly, the TwinGene study used a cross-sectional sampling design and included 144 over 6,000 unrelated subjects born between 1911 and 1958 from the Swedish Twin 145 Registry [9, 10] . CNV calls were generated using Illumina OmniExpress beadchip for 146 72,881 SNP markers and using PennCNV (version June 2011) [11] as the CNV calling 147 algorithm with recommended model parameters. From the full callset, high quality rare 148 CNVs (frequency < 1% and size > 100kb) were extracted to form the simulation pool 149 for the pseudo-CNV data. By mimicking the CNV profiles observed in a population 150 dataset such as TwinGene, the pseudo-CNV data are appropriate for the simulation 151 studies in this work. The pseudo-CNV data are stored in PLINK format indicating 152 individual ID, CNV chromosome and starting and ending locations in base pairs (bp), 153 and CNV dosage (e.g., 0, 1, 2, 3, etc.). 154 For the purpose of simulations we constructed "CNV segments" based on the 155 pseudo-CNV profiles. The endpoints of the segments correspond to locations where a 156 CNV in any one of the samples begins or ends, resulting in segments that contain either 157 one or more intersecting CNVs. Within a segment, CNV dosage of an individual is a 158 constant, and CNVs across individuals may have different dosages but share the same 159 starting and ending positions. Note that different segments will naturally have different 160 lengths. In the simulation study, we built design matrices Z Dup , Z Del , and Z Len which 161 codified CNV features by segment in the pseudo-CNV profile data. The dosage matrices 162 took value 0 for those individuals without CNVs in the segment and were coded as 1 or 163 2 according to the number of additional or missing copies comprising the CNV. Length 164 was the length of the CNV segment in kb for individuals with CNV events and was 0 for 165 individuals without CNVs in the segment.
166
A case-control phenotype was generated from the logistic model
where Z ij • is the (i, j) entry of matrix Z • , i = 1, · · · , N indexes individuals, and Davies' method [13] as implemented in the CKAT R package.
218
Simulation Results
219
The type I error rates of the three tests were examined at nominal levels of 0.01, 0.05, 220 and 0.1 ( Table 1 ). All methods had type I error rates roughly around the nominal level. 221 The proportion of the causal deletion sites out of all deletions was 9.5%, and is 6.9% for 236
duplications. In addition, the 100 causal duplication segments had higher median and including between-locus heterogeneity due to the mixture of deleterious and protective 247 segments, between-locus heterogeneity due to duplication and deletion causal segments, 248
and within-locus heterogeneity due to duplications and deletions with a segment having 249 opposite effects. We observed that CONCUR has the best power among the three tests 250 across different settings, followed by CCRET and then by CKAT. We adjusted for sex, age, BMI, and the top 10 principal components representing the 328 population structure as covariates with fixed effects. As before, CKAT was performed 329
with each pathway comprising a single CNVR. We compared the test results to a 330 Bonferroni threshold of 0.05/15 = 0.00333.
331
Out of the 15 pathways, ten pathways were identified as significantly associated with 332 TG by CONCUR, nine pathways by CKAT, and one pathway by CCRET (Table 3) .
333
There were a total of 12 pathways found significant by one or more methods, among weaker signal in deletions (p-value=0.0313).
377
To further explore the signal from duplications, we visualized CNVs in the 23 genes 378 in hsa01040 ( Fig 6) . Fig 6 displays duplications and (FXR) [24, 25] . Since conversion of cholesterol to bile acid is an essential step in 387 preventing the accumulation of TG, copy number duplications in BAAT may directly 388 affect TG levels in the blood. Three ELO genes had significant CNV associations. Since 389 the major functions of these genes focus on the elongation of fatty acids, CNV events in 390 these genes are likely to affect the production and metabolism of TG. For example, one 391 study showed that hepatic steatosis was observed in ELOVL5 -knockout mice due to the 392 activation of SREBP-1c and its target genes [30] . HSD17B4 is a dehydrogenase, which 393 is able to inhibit the production of DHEA [26] . A previous study showed that TG levels 394
were inversely correlated to DHEA levels in men with type 2 diabetes [27] , suggesting a 395 potential link between CNVs in HSD17B4 and TG levels. We introduce CONCUR to leverage the strength of kernel-based methods to access the 404 collective effects of rare CNVs on disease risk and incorporate several desired features. 405
First, CONCUR permits the quantification of CNV similarity in an CNVR-free manner, 406
avoiding the need of arbitrarily defining CNVRs as in current practice. Second,
407
CONCUR incorporates both length and dosage information via the cAUC kernel, and is 408 capable of detecting dosage, length and length-dosage interaction effects. Third, as the 409 technology for detecting smaller CNVs improves, we expect to observe more length X i = (X i1 , · · · , X ir ) T be the r covariates. Under the kernel machine regression 461 framework, we model the association between phenotypes and CNVs as follows
where "dosage transform functions" as described below, and allow us to compute cAUC 473 similarity from duplications and from deletions in a more flexible manner. 474 We further use q = 1, · · · , P ik to index the CNV features (DS q , BP 1 q , BP 2 q ) occurring on chromosome k of individual i for k = 1, · · · , 22. Then we construct duplication and deletion profile curves respectively describing duplications and deletions on chromosome k for individual i as follows:
where x is a location on the genome on the same scale as BP 1 q and BP 2 q ; I is the as it computes the minimal common area under the two individuals' duplication and 497 deletion profile curves. The cAUC kernel function is a valid kernel as shown in S1 498 Appendix.
499
The intuition of the cAUC kernel is to quantify similarity using the length of The association between phenotype and CNVs is examined by testing the hypothesis 519 H 0 : h(·) = 0. To do so, we define the vector of subject-specific CNV effects 520 H = (h(Z 1 ), · · · , h(Z n )) and treat H as random effects which follow N (0, τ K), where 521 τ ≥ 0 is a variance component and K is a n × n kernel matrix with its (i, j)th entry 
where Y is n × 1 vector of responses; µ 0 = E(Y ) under H 0 ; φ is a dispersion factor 526 parameterizing the variance of Y ; ∆ ∈ R n×n is a diagonal matrix with its ith diagonal 527 element being δ i = 1/g (µ i ); W ∈ R n×n is a diagonal weight matrix with its ith al. [12] derived the corresponding small-sample distribution, which is used to calculate 532 the p-value in this work. S1 Table. Gene-level CONCUR tests on genes in pathway hsa01040. 535 S1 Appendix. Proof of symmetry and positive semi-definiteness of cAUC 536 kernel.
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